Imagenetix, Inc. (OTC: IAGX) is an innovator of natural
bioceutical products designed to enhance human health on a global basis. By
concentrating on human and animal conditions related to inflammation and
obesity, the company has achieved significant advancements in the successful
research, development and commercialization of safe compositions to reduce body
fat and enhance overall body composition. In particular, Imagenetix develops
and formulates proprietary over-the-counter topical creams, skincare products
and nutritional supplements to be marketed globally through multiple channels
of distribution.
In addition to these products, Imagenetix is currently
undertaking research and development initiatives based on a cascade of
inflammatory events shown to be correlative to a number of diseases. The
company’s first therapeutic drug, 1-TDC, was developed for the treatment and
prevention of periodontal disease, and, according to studies by Boston
University, the drug is effective in halting the progression of gum and bone
damage.
Data from the Centers for Disease Control and Prevention
shows the massive market potential for 1-TDC moving forward. According to the
report, approximately 50 percent of all American adults aged 30 or over suffers
from periodontal disease. In adults 65 or older, prevalence rates rise
dramatically to approximately 70 percent of individuals.
“We are excited with… the potential of our compound to
become a major breakthrough for the prevention of periodontal disease,” William
P. Spencer, president of Imagenetix, stated in a news release. The prevalence
of the disease among Americans “creates a potential multi-billion [dollar]
market for a product developed from our compound.”
In recent years, the company’s primary product has been
Celadrin. This medically and clinically proven pain management compound has
been shown to dramatically reduce inflammation and pain, providing Imagenetix
with access to another market with near limitless potential for growth in the
future.
Through a balance of research and development initiatives
and continued marketing of its existing product offerings, Imagenetix could be
in a strong position to realize increased market share in the years to come.
For prospective shareholders, the company’s established presence within the
over-the-counter pharmaceutical industry makes it an interesting investment
opportunity moving forward.
For more information, visit www.imagenetix.com
About QualityStocks
QualityStocks is committed to connecting subscribers with companies that have huge potential to succeed in the short and long-term future. We offer several ways for investors to find, evaluate, and learn more about investing in these companies.
QualityStocks is committed to connecting subscribers with companies that have huge potential to succeed in the short and long-term future. We offer several ways for investors to find, evaluate, and learn more about investing in these companies.
Sign up for “The QualityStocks Daily Newsletter” at www.QualityStocks.net
The Quality Stocks Daily Blog http://blog.qualitystocks.net
The Quality Stocks Daily Videos http://videocharts.qualitystocks.net
The Quality Stocks “Ones to Watch” http://gotstocks.qualitystocks.net
Please see disclaimer on the QualityStocks website: http://disclaimer.qualitystocks.net
No comments:
Post a Comment